secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2025-09-23T23:59:59+00:00
Accession:  0001213900-25-090715
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed reports FY2025 net loss of $8.2M; BayMedica revenue up 8% to $4.9M
------------------------------------------------------------------------

- Net loss $8.2M vs $7.7M prior year; diluted EPS ($8.36) vs ($20.14) on higher share count.
- Cash $11.1M, up from $6.6M; expected to fund operations into Q4 2026.
- BayMedica segment sales $4.9M (+8% YoY); gross profit rose to $1.7M from $1.1M.
- INM-901 Alzheimer's candidate: significant neuroinflammation reductions and oral bioavailability data.
- INM-089 dry AMD program selected intravitreal formulation; doses up to 10x safety margin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025090715/0001213900-25-090715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025090715/ea0258458-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-090715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer